Skip to main content
TipRanks
Go Ultimate75% OFF

Aptamer Group Plc (P0J) AI Stock Analysis

1 Followers
DE:P0J

Aptamer Group Plc

(Frankfurt:P0J)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Balance Sheet StrengthThe sharp increase in equity and very low leverage provide a stronger financial cushion than in prior years. Limited debt reduces interest and refinancing pressure, giving Aptamer Group more flexibility to support operations while it works toward sustainable profitability.
Negative Factors
Persistent LossesDeeply negative profitability shows that current revenue is insufficient to cover the company’s operating cost base. Continued losses constrain internal reinvestment, weaken shareholder returns, and leave execution dependent on achieving substantially greater scale or reducing costs.

Aptamer Group Plc (P0J) vs. iShares MSCI Germany ETF (EWG)

-25%0%25%50%75%100%125%150%DE:P0J+100.00%EWG+9.20%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 12.14M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-11.7
Beta (1Y)
-3.60
Revenue Growth
24.08%
EPS Growth
56.25%
Country
Germany
Employees
34
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Aptamer Group Plc Business Overview & Revenue Model

Company Description

Aptamer Group plc, an international company headquartered in York, United Kingdom, specializes in providing advanced binders for applications spanning research, diagnostics, and therapeutics. Their innovative binder technology is engineered to resolv...

Aptamer Group Plc Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:P0J against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:BVXPGB:BVXP89OutperformGBP 101.88M13.4567.81%7.69%-1.10%0.32%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:AVCTGB:AVCT40UnderperformGBP 277.96M-6.26-1293.07%―――
GB:FABGB:FAB40UnderperformGBP 5.32M-4.29-97.87%―7.38%44.13%
GB:OBDGB:OBD40UnderperformGBP 15.46M-0.29-451.74%―33.37%86.41%
GB:ARECGB:AREC33UnderperformGBP 35.11M155.003.75%―――

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%150%DE:P0JGB:AVCTGB:BVXPGB:OBDGB:FABGB:ARECDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:P0J and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:P0JAptamer Group Plc0.020.01100.00%
GB:AVCTAvacta Group plc57.10-22.90-28.63%
GB:BVXPBioventix plc1950.00-37.97-1.91%
GB:OBDOxford BioDynamics0.12-0.17-58.93%
GB:FABFusion Antibodies Plc4.25-8.00-65.31%
GB:ARECArecor Therapeutics PLC77.503.504.73%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.